Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Lionel Riou França"'
Autor:
Tahseen Mozaffar, Lionel Riou França, Jérôme Msihid, Pragya Shukla, Irina Proskorovsky, Tianyue Zhou, Magali Periquet, Kristina An Haack, Laurence Pollissard, Volker Straub
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 40, Iss , Pp 101109- (2024)
Background: The efficacy of avalglucosidase alfa (AVA) versus alglucosidase alfa (ALG) on forced vital capacity percent predicted (FVCpp) in patients with late-onset Pompe disease (LOPD) has been assessed in the Phase 3 COMET trial (NCT02782741). Due
Externí odkaz:
https://doaj.org/article/8c1269ee7f074a86a443bd3cdd49e43a
Autor:
Matthias Boentert, Kenneth I. Berger, Jordi Díaz-Manera, Mazen M. Dimachkie, Alaa Hamed, Lionel Riou França, Nathan Thibault, Pragya Shukla, Jack Ishak, J. Jaime Caro
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-8 (2024)
Abstract Background Clinical trials for rare diseases often include multiple endpoints that capture the effects of treatment on different disease domains. In many rare diseases, the primary endpoint is not standardized across trials. The win ratio ap
Externí odkaz:
https://doaj.org/article/e7b737f3c80f41c2a3616eefc9531926
Autor:
Sergio J. Dubner, Christine Teutsch, Menno V. Huisman, Hans‐Christoph Diener, Jonathan Halperin, Kenneth J. Rothman, Chang‐Sheng Ma, Eduardo Chuquiure‐Valenzuela, Jutta Bergler‐Klein, Kristina Zint, Lionel Riou França, Shihai Lu, Miney Paquette, Gregory Y.H. Lip
Publikováno v:
ESC Heart Failure, Vol 7, Iss 5, Pp 2679-2689 (2020)
Abstract Aims This study aimed to describe baseline characteristics of patients with atrial fibrillation (AF) at risk of stroke with and without history of heart failure (HF) and report 2‐year outcomes in the dabigatran‐treated subset of a prospe
Externí odkaz:
https://doaj.org/article/1522bd1b64b64f8eac2f79e375dd301a
Autor:
Changsheng Ma, Lionel Riou França, Shihai Lu, Hans‐Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Qiang Li, Miney Paquette, Christine Teutsch, Menno V. Huisman, Gregory Y. H. Lip, Kenneth J. Rothman, the GLORIA‐AF Investigators
Publikováno v:
Journal of Arrhythmia, Vol 36, Iss 3, Pp 408-416 (2020)
Abstract Background Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of
Externí odkaz:
https://doaj.org/article/2fffc4ffe41f4be588b417b800bc3d2d
Autor:
Lea Beier, Shihai Lu, Lionel Riou França, Sabrina Marler, Gregory Y. H. Lip, Menno V. Huisman, Christine Teutsch, Jonathan L. Halperin, Kristina Zint, Hans-Christoph Diener, Laurie Baker, Chang-Sheng Ma, Miney Paquette, Dorothee B. Bartels, Sergio J. Dubner, Philippe Lyrer, Jochen Senges, Kenneth J. Rothman
Publikováno v:
PLoS ONE, Vol 17, Iss 10 (2022)
Objective To assess baseline characteristics and antithrombotic treatment (ATT) prescription patterns in patients enrolled in the third phase of the GLORIA-AF Registry Program, evaluate predictors of treatment prescription, and compare results with p
Externí odkaz:
https://doaj.org/article/0dba4151a4414a9b9f78f839222becf5
Autor:
Sake J. van der Wall, Christine Teutsch, Sergio J. Dubner, Hans-Christoph Diener, Jonathan L. Halperin, Chang Sheng Ma, Kenneth J. Rothman, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Gregory Y. H. Lip, Menno V. Huisman
Publikováno v:
TH Open, Vol 05, Iss 01, Pp e35-e42 (2021)
Objective Anticoagulation management in patients with atrial fibrillation (AF) and impaired renal function is challenging. This study aimed to evaluate anticoagulation prescription patterns in relation to renal function and to describe 2-year clinica
Externí odkaz:
https://doaj.org/article/fe4f963d8c3145c5988f99f3efdf9830
Autor:
Monika Kozieł, Michał Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang-Sheng Ma, Kenneth J. Rothman, Axel Brandes, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B. Bartels, Menno V. Huisman, Gregory Y. H. Lip
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 6, p 1969 (2020)
Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy p
Externí odkaz:
https://doaj.org/article/2c4e09a4877f49c380f360b649cf26ba
Autor:
Jordi Diaz-Manera, Mazen M. Dimachkie, Jack Ishak, Jaime Caro, Alaa Hamed, Lionel Riou França, Nathan Thibault, Pragya Shukla, Kenneth I. Berger, Matthias Boentert
Publikováno v:
Molecular Genetics and Metabolism. 138:107076
Autor:
Shihai Lu, Gregory Y.H. Lip, Jonathan L. Halperin, Kristina Zint, Kenneth J. Rothman, Chang Sheng Ma, Miney Paquette, Lionel Riou França, Robby Nieuwlaat, Hans-Christoph Diener, Brian Olshansky, Menno V. Huisman, Sergio Dubner, Christine Teutsch
Publikováno v:
Paquette, M, França, L R, Teutsch, C, Diener, H-C, Lu, S, Dubner, S J, Ma, C S, Rothman, K J, Zint, K, Halperin, J L, Olshansky, B, Huisman, M V, Lip, G Y H & Nieuwlaat, R 2020, ' Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry ', The American Journal of Cardiology, vol. 125, no. 3, pp. 383-391 . https://doi.org/10.1016/j.amjcard.2019.10.047
Prospective studies evaluating persistence to nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation are needed to improve our understanding of drug discontinuation. The study objective was to evaluate if and when patients w
Autor:
Michał Mazurek, Hans-Christoph Diener, Shihai Lu, Jonathan L. Halperin, Dorothee B. Bartels, Miney Paquette, Lionel Riou França, Sergio Dubner, Menno V. Huisman, Gregory Y.H. Lip, Changsheng Ma, Kristina Zint, Christine Teutsch, Kenneth J. Rothman, Gloria-Af Investigators
Publikováno v:
American Heart Journal, 218, 123-127. MOSBY-ELSEVIER
American heart journal
American heart journal
GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients with newly diagnosed atrial fibrillation (AF) in clinical practice. Thi